CoChat

Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth

Open access
Lei, Ming-Zhu, Li, Xu-Xu, Zhang, Ye, Li, Jin-Tao, Zhang, Fan, Wang, Yi-Ping, Yin, Miao, Qu, Jia, Lei, Qun-Ying · 2020 · Signal Transduction and Targeted Therapy

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is well-known for inefficient early diagnosis, with most patients diagnosed at advanced stages. Increasing evidence indicates that elevated plasma levels of branched-chain amino acids (BCAAs) are associated with an increased risk of pancreatic cancer. Branched-chain amino acid transaminase 2 (BCAT2) is an important enzyme in BCAA catabolism that reversibly catalyzes the initial step of BCAA degradation to branched-chain acyl-CoA. Here, we show that BCAT2 is acetylated at lysine 44 (K44), an evolutionarily conserved residue. BCAT2 acetylation leads to its degradation through the ubiquitin–proteasome pathway and is stimulated in response to BCAA deprivation. cAMP-responsive element-binding (CREB)-binding protein (CBP) and SIRT4 are the acetyltransferase and deacetylase for BCAT2, respectively. CBP and SIRT4 bind to BCAT2 and control the K44 acetylation level in response to BCAA availability. More importantly, the K44R mutant promotes BCAA catabolism, cell proliferation, and pancreatic tumor growth. Collectively, the data from our study reveal a previously unknown regulatory mechanism of BCAT2 in PDAC and provide a potential therapeutic target for PDAC treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41392-020-0168-0

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 BCAT2 is acetylated mainly at lysine 44. a Diagram of the BCAA catabolic pathway. As shown, branched-chain amino acids (leucine, isoleucine, and valine) are reversibly transaminated by branched-chain amino acid transaminase 1/2 to produce BCKA. b Exogenous BCAT2 is acetylated. Flag-BCAT2 WT was ectopically expressed in HEK293T cells and treated with the deacetylase inhibitors NAM (5 mM, 6 h) and TSA (10 μM, 16 h). BCAT2 acetylation was detected with an anti-acetyl lysine (Pan-Ac) antibody by western blotting. The relative BCAT2 acetylation level was normalized to that of Flag-BCAT2 protein. c NAM treatment increases BCAT2 acetylation in a dose-dependent manner. Flag-BCAT2 was transfected into HEK293T cells. Cells were treated with NAM at the indicated concentrations for 6 h. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. d The K44R mutant has decreased BCAT2 acetylation. Flag-BCAT2 WT and the K44R mutant were ectopically expressed in HEK293T cells, and BCAT2 acetylation was measured by western blotting. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. e K44 is conserved and located in the N-terminus. The sequences around BCAT2 K44 from different species were aligned. f The K44 site-specific acetylation antibody can detect the acetylated peptide, but not detect an unmodified peptide. The different amounts of either acetylated K44 peptide or unmodified peptide were spotted onto a nitrocellulose membrane, as indicated, and probed with the anti-Ac BCAT2 (K44) antibody (K44Ac). g The K44Ac peptide, but not the unmodified peptide, blocks the K44 site-specific antibody. The K44Ac antibody was incubated with K44Ac peptide or an unmodified peptide for 3 h at 4 °C and used in western blotting. The BCAT2 antibody was included as a control. h NAM increases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were treated with NAM for the indicated times. Endogenous BCAT2 protein was purified and detected with K44Ac antibody. The relative BCAT2 K44 acetylation level was normalized to that of BCAT2 protein. Data are representative of three independent experiments in b, c, d, f, g, h
Fig. 1 BCAT2 is acetylated mainly at lysine 44. a Diagram of the BCAA catabolic pathway. As shown, branched-chain amino acids (leucine, isoleucine, and valine) are reversibly transaminated by branched-chain amino acid transaminase 1/2 to produce BCKA. b Exogenous BCAT2 is acetylated. Flag-BCAT2 WT was ectopically expressed in HEK293T cells and treated with the deacetylase inhibitors NAM (5 mM, 6 h) and TSA (10 μM, 16 h). BCAT2 acetylation was detected with an anti-acetyl lysine (Pan-Ac) antibody by western blotting. The relative BCAT2 acetylation level was normalized to that of Flag-BCAT2 protein. c NAM treatment increases BCAT2 acetylation in a dose-dependent manner. Flag-BCAT2 was transfected into HEK293T cells. Cells were treated with NAM at the indicated concentrations for 6 h. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. d The K44R mutant has decreased BCAT2 acetylation. Flag-BCAT2 WT and the K44R mutant were ectopically expressed in HEK293T cells, and BCAT2 acetylation was measured by western blotting. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. e K44 is conserved and located in the N-terminus. The sequences around BCAT2 K44 from different species were aligned. f The K44 site-specific acetylation antibody can detect the acetylated peptide, but not detect an unmodified peptide. The different amounts of either acetylated K44 peptide or unmodified peptide were spotted onto a nitrocellulose membrane, as indicated, and probed with the anti-Ac BCAT2 (K44) antibody (K44Ac). g The K44Ac peptide, but not the unmodified peptide, blocks the K44 site-specific antibody. The K44Ac antibody was incubated with K44Ac peptide or an unmodified peptide for 3 h at 4 °C and used in western blotting. The BCAT2 antibody was included as a control. h NAM increases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were treated with NAM for the indicated times. Endogenous BCAT2 protein was purified and detected with K44Ac antibody. The relative BCAT2 K44 acetylation level was normalized to that of BCAT2 protein. Data are representative of three independent experiments in b, c, d, f, g, hCC BY · PubMed Central
Fig. 2 Acetylation promotes BCAT2 degradation without affecting its enzymatic activity. a NAM treatment decreases BCAT2 protein levels. HEK293T cells were treated with NAM, TSA, or both for the indicated times. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b NAM decreases BCAT2 protein in HEK293T and different PDAC cell lines. HEK293T, BxPC-3, PANC-1, and SW1990 cells were treated with NAM for the indicated times. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c NAM has a negligible effect on BCAT2 mRNA levels. HEK293T, BxPC-3, PANC-1, and SW1990 cells were treated with NAM for the indicated times. The relative BCAT2 mRNA levels were determined by qPCR and normalized to the level of ACTB. Results are expressed as the means ± SEM of three independent experiments. d MG132 blocks NAM/TSA-induced BCAT2 degradation. HEK293T cells were treated with or without NAM/TSA in the presence or absence of MG132 (10 μM, 6 h). The relative BCAT2 protein level was normalized to that of β-actin. e The K44R mutant has lower BCAT2 ubiquitylation levels. Flag-BCAT2 WT and the K44R mutant were coexpressed with HA-UB in HEK293T cells, and ubiquitylation of the purified protein was determined. f NAM increases Flag-BCAT2 WT ubiquitylation, but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were co-transfected with HA-UB into HEK293T cells with or without NAM treatment for the indicated time, and the ubiquitylation of the purified protein was determined. g Flag-BCAT2 WT activity is not significantly different from that of the K44 mutants. Flag-BCAT2 WT and the K44 mutants were expressed in HEK293T cells. The activity level of the immunopurified BCAT2 was determined. Results are expressed as the means ± SEM of four independent experiments. Significance was assessed by Student’s t test (c, g). n.s. no significance. Data are representative of three independent experiments in a, b, c, d, e, and f
Fig. 2 Acetylation promotes BCAT2 degradation without affecting its enzymatic activity. a NAM treatment decreases BCAT2 protein levels. HEK293T cells were treated with NAM, TSA, or both for the indicated times. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b NAM decreases BCAT2 protein in HEK293T and different PDAC cell lines. HEK293T, BxPC-3, PANC-1, and SW1990 cells were treated with NAM for the indicated times. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c NAM has a negligible effect on BCAT2 mRNA levels. HEK293T, BxPC-3, PANC-1, and SW1990 cells were treated with NAM for the indicated times. The relative BCAT2 mRNA levels were determined by qPCR and normalized to the level of ACTB. Results are expressed as the means ± SEM of three independent experiments. d MG132 blocks NAM/TSA-induced BCAT2 degradation. HEK293T cells were treated with or without NAM/TSA in the presence or absence of MG132 (10 μM, 6 h). The relative BCAT2 protein level was normalized to that of β-actin. e The K44R mutant has lower BCAT2 ubiquitylation levels. Flag-BCAT2 WT and the K44R mutant were coexpressed with HA-UB in HEK293T cells, and ubiquitylation of the purified protein was determined. f NAM increases Flag-BCAT2 WT ubiquitylation, but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were co-transfected with HA-UB into HEK293T cells with or without NAM treatment for the indicated time, and the ubiquitylation of the purified protein was determined. g Flag-BCAT2 WT activity is not significantly different from that of the K44 mutants. Flag-BCAT2 WT and the K44 mutants were expressed in HEK293T cells. The activity level of the immunopurified BCAT2 was determined. Results are expressed as the means ± SEM of four independent experiments. Significance was assessed by Student’s t test (c, g). n.s. no significance. Data are representative of three independent experiments in a, b, c, d, e, and fCC BY · PubMed Central
Fig. 3 BCAA deprivation promotes BCAT2 acetylation and degradation. a BCAA and glutamine deprivation decreases BCAT2 protein levels. SW1990 cells were maintained in BCAA or glutamine-free medium for 24 h. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b MG132 blocks BCAA deprivation-induced BCAT2 degradation. SW1990 cells were maintained in BCAA-free medium for 24 h, and treated with or without MG132 (10 μM, 6 h). Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c BCAA deprivation increases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were maintained in BCAA-free medium for 24 h, and treated with MG132 for 6 h. Cell lysates were analyzed by western blotting. The relative K44Ac acetylation level was normalized to that of BCAT2. d BCAA deprivation increases Flag-BCAT2 WT acetylation, but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were expressed in HEK293T cells and treated with NAM. BCAT2 acetylation was detected with K44Ac antibody. The relative K44Ac acetylation level was normalized to that of Flag-BCAT2. e BCAA deprivation increases Flag-BCAT2 WT ubiquitylation but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were co-transfected with HA-UB into HEK293T cells. Cells were maintained in BCAA-free medium for 24 h, and the ubiquitylation of the purified protein was determined. f The K44R mutant is more stable than Flag-BCAT2 WT under BCAA deprivation. Stable Flag-BCAT2 and K44R mutant cells were maintained in BCAA-free medium for 24 h, and treated with CHX (10 μg/mL) for the indicated time course. BCAT2 protein was analyzed by western blotting. Quantification of the BCAT2 protein levels is shown. The results are expressed as the means ± SEM of three independent experiments. Significance was assessed by Student’s t test. *P < 0.05, **P < 0.01. Data are representative of three independent experiments in a, b, c, d, e, and f
Fig. 3 BCAA deprivation promotes BCAT2 acetylation and degradation. a BCAA and glutamine deprivation decreases BCAT2 protein levels. SW1990 cells were maintained in BCAA or glutamine-free medium for 24 h. Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b MG132 blocks BCAA deprivation-induced BCAT2 degradation. SW1990 cells were maintained in BCAA-free medium for 24 h, and treated with or without MG132 (10 μM, 6 h). Cell lysates were analyzed by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c BCAA deprivation increases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were maintained in BCAA-free medium for 24 h, and treated with MG132 for 6 h. Cell lysates were analyzed by western blotting. The relative K44Ac acetylation level was normalized to that of BCAT2. d BCAA deprivation increases Flag-BCAT2 WT acetylation, but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were expressed in HEK293T cells and treated with NAM. BCAT2 acetylation was detected with K44Ac antibody. The relative K44Ac acetylation level was normalized to that of Flag-BCAT2. e BCAA deprivation increases Flag-BCAT2 WT ubiquitylation but not that of the K44R mutant. Flag-BCAT2 WT and the K44R mutant were co-transfected with HA-UB into HEK293T cells. Cells were maintained in BCAA-free medium for 24 h, and the ubiquitylation of the purified protein was determined. f The K44R mutant is more stable than Flag-BCAT2 WT under BCAA deprivation. Stable Flag-BCAT2 and K44R mutant cells were maintained in BCAA-free medium for 24 h, and treated with CHX (10 μg/mL) for the indicated time course. BCAT2 protein was analyzed by western blotting. Quantification of the BCAT2 protein levels is shown. The results are expressed as the means ± SEM of three independent experiments. Significance was assessed by Student’s t test. *P < 0.05, **P < 0.01. Data are representative of three independent experiments in a, b, c, d, e, and fCC BY · PubMed Central
Fig. 4 CBP acetylates BCAT2 to promote its degradation. a Overexpression of CBP increases BCAT2 acetylation levels. Flag-BCAT2 was expressed in HEK293T cells in combination with Flag-PCAF, Flag-P300, Flag-CBP, and Myc-GCN5. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. b Overexpression of CBP decreases endogenous BCAT2 levels. Flag-PCAF, Flag-P300, Flag-CBP, and Myc-GCN5 were ectopically expressed in HEK293T cells. Endogenous BCAT2 was determined by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c CBP knockdown decreases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were transfected with siCBP or siNC. Endogenous BCAT2 protein was purified and detected with K44Ac antibody. The relative BCAT2 K44 acetylation level was normalized to that of the BCAT2 protein. d Overexpression of CBP increases BCAT2 ubiquitylation. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with Flag-CBP and HA-UB. The ubiquitylation of the purified protein was determined. e His-BCAT2 pulls down CBP. BL21 E. coli transformed with the pGEX-His-BCAT2 plasmid was induced (or not induced) by isopropyl-b-D-thiogalactoside. Protein was then purified with Ni-NTA agarose beads and incubated with SW1990 cell lysates before repurification with immunoprecipitation and subjected to western blotting. Data are representative of three independent experiments in a, b, c, d, and e
Fig. 4 CBP acetylates BCAT2 to promote its degradation. a Overexpression of CBP increases BCAT2 acetylation levels. Flag-BCAT2 was expressed in HEK293T cells in combination with Flag-PCAF, Flag-P300, Flag-CBP, and Myc-GCN5. The relative BCAT2 acetylation level was normalized to that of the Flag-BCAT2 protein. b Overexpression of CBP decreases endogenous BCAT2 levels. Flag-PCAF, Flag-P300, Flag-CBP, and Myc-GCN5 were ectopically expressed in HEK293T cells. Endogenous BCAT2 was determined by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. c CBP knockdown decreases endogenous BCAT2 acetylation. SW1990 and PANC-1 cells were transfected with siCBP or siNC. Endogenous BCAT2 protein was purified and detected with K44Ac antibody. The relative BCAT2 K44 acetylation level was normalized to that of the BCAT2 protein. d Overexpression of CBP increases BCAT2 ubiquitylation. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with Flag-CBP and HA-UB. The ubiquitylation of the purified protein was determined. e His-BCAT2 pulls down CBP. BL21 E. coli transformed with the pGEX-His-BCAT2 plasmid was induced (or not induced) by isopropyl-b-D-thiogalactoside. Protein was then purified with Ni-NTA agarose beads and incubated with SW1990 cell lysates before repurification with immunoprecipitation and subjected to western blotting. Data are representative of three independent experiments in a, b, c, d, and eCC BY · PubMed Central
Fig. 5 BCAT2 is stabilized by SIRT4 deacetylation. a SIRT4 overexpression increases endogenous BCAT2 protein levels. HA-SIRT1-7 was expressed in HEK293T cells. Endogenous BCAT2 was determined by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b SIRT4 deacetylates BCAT2. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with SIRT4 WT and H161Y mutant. The relative BCAT2 acetylation level was normalized to that of Flag-BCAT2. c Bcat2 is decreased in Sirt4-knockout (KO) MEFs. Bcat2 protein was determined by western blotting. Relative Bcat2 protein level was normalized to β-actin. d Overexpression of SIRT4 decreases BCAT2 ubiquitylation. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with SIRT4 WT and HA-UB. The ubiquitylation of purified protein was determined. e Sirt4 KO destabilizes Bcat2 in MEFs. Sirt4 WT and KO MEFs were subjected to CHX treatment (10 μg/mL) for the indicated time course. Bcat2 protein was analyzed by western blotting. Quantified Bcat2 protein levels are shown. The results are expressed as the mean ± SEM of three independent experiments. The significance was assessed by Student’s t test. *P < 0.05, **P < 0.05. f His-BCAT2 readily pulls down SIRT4. BL21 E. coli transformed with the pGEX-His-BCAT2 plasmid was induced (or not induced) by isopropyl-b-D-thiogalactoside. Protein was then purified through a Ni-NTA column and incubated with SW1990 cell lysates before repurification with immunoprecipitation and subjected to western blotting. Data are representative of three independent experiments in a, b, c, d, e, and f
Fig. 5 BCAT2 is stabilized by SIRT4 deacetylation. a SIRT4 overexpression increases endogenous BCAT2 protein levels. HA-SIRT1-7 was expressed in HEK293T cells. Endogenous BCAT2 was determined by western blotting. The relative BCAT2 protein level was normalized to that of β-actin. b SIRT4 deacetylates BCAT2. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with SIRT4 WT and H161Y mutant. The relative BCAT2 acetylation level was normalized to that of Flag-BCAT2. c Bcat2 is decreased in Sirt4-knockout (KO) MEFs. Bcat2 protein was determined by western blotting. Relative Bcat2 protein level was normalized to β-actin. d Overexpression of SIRT4 decreases BCAT2 ubiquitylation. Flag-BCAT2 was ectopically expressed in HEK293T cells in combination with SIRT4 WT and HA-UB. The ubiquitylation of purified protein was determined. e Sirt4 KO destabilizes Bcat2 in MEFs. Sirt4 WT and KO MEFs were subjected to CHX treatment (10 μg/mL) for the indicated time course. Bcat2 protein was analyzed by western blotting. Quantified Bcat2 protein levels are shown. The results are expressed as the mean ± SEM of three independent experiments. The significance was assessed by Student’s t test. *P < 0.05, **P < 0.05. f His-BCAT2 readily pulls down SIRT4. BL21 E. coli transformed with the pGEX-His-BCAT2 plasmid was induced (or not induced) by isopropyl-b-D-thiogalactoside. Protein was then purified through a Ni-NTA column and incubated with SW1990 cell lysates before repurification with immunoprecipitation and subjected to western blotting. Data are representative of three independent experiments in a, b, c, d, e, and fCC BY · PubMed Central
Fig. 6 The K44R mutant promotes pancreatic cancer growth. a Verification of the stable SW1990 cell lines. BCAT2 was stably knocked down with shRNA in SW1990 cells. shRNA-resistant Flag-BCAT2 WT and K44R/Q mutants were stably re-expressed, and the knockdown efficiency and re-expression levels were determined by western blotting. b The K44 mutants promote cell proliferation. Cells were seeded in 12-well plates in BCAA-free medium. Cells were counted every 48 h. Error bars represent cell number ± SEM for experiments performed in triplicate. c The K44R mutant promotes colony formation. The cells were seeded in six-well plates and maintained in BCAA-free medium or normal medium. The results are expressed as the means ± S.D. of three independent experiments. d The K44R mutant has increased BCAA uptake. The cells were pretreated with BCAA-free medium or normal medium for 24 h. Then, after the cells were grown for 24 h, the BCAA concentration in the culture medium was measured. The results are expressed as the means ± S.D. of three independent experiments. e The K44R mutant promotes tumor growth in vivo. A subcutaneous xenograft experiment was performed with nude mice using BCAT2-knockdown SW1990 cells re-expressing Flag-BCAT2 WT and the K44R mutant. Xenograft tumors were dissected, and their weight and volume were determined. WT: mean ± SEM of n = 6; K44R: mean ± SEM of n = 6. f The K44R mutant in the tumor xenograft samples has increased Ki67 staining. Cells were quantified and analyzed (right). The percentage of Ki67-positive cells is presented as the mean ± S.D. calculated from three different views. Significance was assessed by Student’s t test (c–e, f) and one-way ANOVA (b). *P < 0.05, **P < 0.01, n.s. no significance. Scale bar, 50 µm. Data are representative of three independent experiments as shown in a, c, d. g Working model depicting how acetylation at K44 promotes BCAT2 degradation in response to BCAA deprivation. This downregulated expression of BCAT2 contributes to the suppression of BCAA catabolism and tumor cell proliferation
Fig. 6 The K44R mutant promotes pancreatic cancer growth. a Verification of the stable SW1990 cell lines. BCAT2 was stably knocked down with shRNA in SW1990 cells. shRNA-resistant Flag-BCAT2 WT and K44R/Q mutants were stably re-expressed, and the knockdown efficiency and re-expression levels were determined by western blotting. b The K44 mutants promote cell proliferation. Cells were seeded in 12-well plates in BCAA-free medium. Cells were counted every 48 h. Error bars represent cell number ± SEM for experiments performed in triplicate. c The K44R mutant promotes colony formation. The cells were seeded in six-well plates and maintained in BCAA-free medium or normal medium. The results are expressed as the means ± S.D. of three independent experiments. d The K44R mutant has increased BCAA uptake. The cells were pretreated with BCAA-free medium or normal medium for 24 h. Then, after the cells were grown for 24 h, the BCAA concentration in the culture medium was measured. The results are expressed as the means ± S.D. of three independent experiments. e The K44R mutant promotes tumor growth in vivo. A subcutaneous xenograft experiment was performed with nude mice using BCAT2-knockdown SW1990 cells re-expressing Flag-BCAT2 WT and the K44R mutant. Xenograft tumors were dissected, and their weight and volume were determined. WT: mean ± SEM of n = 6; K44R: mean ± SEM of n = 6. f The K44R mutant in the tumor xenograft samples has increased Ki67 staining. Cells were quantified and analyzed (right). The percentage of Ki67-positive cells is presented as the mean ± S.D. calculated from three different views. Significance was assessed by Student’s t test (c–e, f) and one-way ANOVA (b). *P < 0.05, **P < 0.01, n.s. no significance. Scale bar, 50 µm. Data are representative of three independent experiments as shown in a, c, d. g Working model depicting how acetylation at K44 promotes BCAT2 degradation in response to BCAA deprivation. This downregulated expression of BCAT2 contributes to the suppression of BCAA catabolism and tumor cell proliferationCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Cited by

See all 133

Metadata

Authors
Lei, M.-Z., Li, X.-X., Zhang, Y., Li, J.-T., Zhang, F., Wang, Y.-P., Yin, M., Qu, J., & Lei, Q.-Y.
Affiliations
Shanghai Medical College of Fudan University (CN)
Corresponding author
  • Qu, Jia
  • Lei, Qun-Ying
Venue
Signal Transduction and Targeted Therapy
Published
2020-05-29
Volume
5
Issue
1
Pages
70-70
ISSN
2059-3635 (ISSN-L)
OpenAlex
W3031710066
Cited by
129
References
37
Citations by year
2026: 19 · 2025: 25 · 2024: 26 · 2023: 29 · 2022: 13 · 2021: 15 · 2020: 2
FWCI
5.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (81802745, 81790253, 81790250, 91959202)
  • Shanghai Municipal Education Commission (N173606)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
BCAT2, lysine acetylation, pancreatic ductal adenocarcinoma, branched-chain amino acids, BCAA catabolism, protein degradation, ubiquitin-proteasome system, CBP, SIRT4, tumor growth, therapeutic target
MeSH terms
Acetylation, Amino Acids, Branched-Chain, Transaminases, Humans, Neoplasm Proteins, Pancreatic Neoplasms, Pregnancy Proteins, Minor Histocompatibility Antigens, Cell Line, Tumor, HEK293 Cells, Proteolysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. https://app.cochat.ai/papers/10.1038/s41392-020-0168-0
The paper
Lei, M.-Z., Li, X.-X., Zhang, Y., Li, J.-T., Zhang, F., Wang, Y.-P., Yin, M., Qu, J., & Lei, Q.-Y. (2020). Acetylation promotes BCAT2 degradation to suppress BCAA catabolism and pancreatic cancer growth. Signal Transduction and Targeted Therapy. https://doi.org/10.1038/s41392-020-0168-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.